Evidence map›Paper›PMID 41915366›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026

Very high-power short duration radiofrequency ablation to achieve pulmonary vein isolation: the AIR HPSD registry.

Teresa Strisciuglio, Roberto Mantovan, Francesco Solimene, Sara Poggi, Antoine Lepillier, Andrea Giomi, Marco Scaglione, Massimo Grimaldi, Marzia Giaccardi, Luca Rossi and 27 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Teresa StrisciuglioUniversità Federico II, Napoli, Italy.
Roberto MantovanConegliano Hospital - ULSS 2 Marca Trevigiana, Conegliano, TV, Italy.
Francesco SolimeneClinica Montevergine, Mercogliano, AV, Italy.
Sara PoggiMediterranea Cardiocentro, Napoli, Italy.
Antoine LepillierCentre Cardiologique du Nord, Saint Denis, France.
Andrea GiomiSanta Maria Nuova Hospital, Firenze, Italy.
Marco ScaglioneOspedale Cardinal Massaia, Asti, Italy.
Massimo GrimaldiRegional General Hospital Miulli, Acquaviva delle Fonti, Italy.
Marzia GiaccardiSanta Maria Annunziata Hospital, Firenze, Italy.
Luca RossiOspedale Guglielmo da Saliceto, Piacenza, Italy.
Saverio IacopinoMaria Cecilia Hospital , GVM Care & research, Cotignola (RA), Italy.
Piotr KulakowskiMedical University of Warsaw, Warsaw, Poland.
Tomasz KrynskiCenter of Postgraduate Medical Education, Warsaw, Poland.
Matteo AnselminoA.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy.
Antonio Dello RussoMarche University Hospital, Ancona, Italy.
Paolo CompagnucciMarche University Hospital, Ancona, Italy.
Claire A MartinRoyal Papworth Hospital, United Kingdom of Great Britain & Northern, Cambridge, United Kingdom of Great Britain & Northern, Ireland.
Kiran KangUniversity of Cambridge, Cambridge, UK.
Adrian GwizdalaFirst Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.
Marcello Anders PiacentiFondazione Toscana Gabriele Monasterio, Pisa, Italy.
Maria Luisa LoricchioSandro Pertini Hospital, Rome, Italy.
Graziana ViolaSS Trinità Hospital, ASL 8 Cagliari, Cagliari, Italy.
Giulio ZucchelliAzienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Kaspars KupicsPaul Stradins Clinical University Hospital, Riga, Latvia.
Luca RebellatoOspedale S. Maria della Misericordia (ASUFC), Udine, Italy.
Procolo MarcheseAST Ascoli Piceno, Ascoli Piceno, Italy.
Claudio PandoziPresidio Ospedaliero San Filippo Neri, Roma, Italy.
Alexandre BodinCentre Hospitalier Régional Universitaire de Tours, Tours, France.
Giacomo MugnaiAzienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Gemma PalergonioFondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Maria Lucia NarducciFondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Marco GallucciConegliano Hospital - ULSS 2 Marca Trevigiana, Conegliano, TV, Italy.
Vincenzo SchillaciClinica Montevergine, Mercogliano, AV, Italy.
Sarah ZeriouhRoyal Papworth Hospital, United Kingdom of Great Britain & Northern, Cambridge, United Kingdom of Great Britain & Northern, Ireland.
Ieva AnsabergaPaul Stradins Clinical University Hospital, Riga, Latvia.
Kristine JubelePaul Stradins Clinical University Hospital, Riga, Latvia.
Giuseppe StabileMediterranea Cardiocentro, Napoli, Italy. gmrstabile@tin.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe QDOT Micro catheter allows to perform a very high-power short-duration ablation that produces wider and shallower lesions. This study aims to corroborate the evidences on the safety, acute and long-term efficacy of this catheter by providing a large real-world dataset.

methodsThe AIR HPSD Registry is a multicentric prospective registry across 26 European centers that enrolled consecutive atrial fibrillation (AF) patients undergoing their first pulmonary vein (PV) isolation. In all patients a wide antrum circumferential ablation aimed at PV isolation was performed using the QDOT Micro catheter in QMode+ (90 w for 4 s) for the whole ablation or in a hybrid mode (QMode + for the posterior wall and QMode guided by ablation index for the anterior wall), according to the operators’ preference.

resultsOverall, 982 patients have been enrolled, 38% of patients were ablated with the QMode + solely and 62% with a hybrid modality. The fluoroscopy time was higher in the hybrid group (396 ± 493 s vs. 138 ± 238 s, p < 0.001) and similarly the procedural time (112 ± 41 min vs. 96 ± 36 min, p = 0.01). The complications (1.8%) were similar between groups (1.1% in Qmode+ group vs. 2.3% in hybrid group, p = 0.3). The freedom from AF/AT recurrence was similar between groups (88% hybrid group vs. 90% Qmode+ group, p = ns) and higher in paroxysmal than in persistent patients (90% vs. 81%, p < 0.001).

conclusionThe QDOT Micro catheter demonstrated high efficiency, safety, and effectiveness in achieving PV isolation in patients undergoing their first ablation for paroxysmal or persistent AF.

Indexed as

Atrial fibrillationCatheter ablationVery high-power short duration

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.